Document Detail


Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice.
MedLine Citation:
PMID:  23149196     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Etanercept is well tolerated and effective in moderate to severe psoriasis; however, data on patient-reported outcomes (PROs) in Canadian patients remain limited.
OBJECTIVE: To assess PROs in Canadian patients with moderate to severe psoriasis receiving etanercept in an open-label trial more representative of general clinical practice than traditional research studies.
METHODS: This 1-year, multicenter, single-arm study enrolled 246 patients. Patients received etanercept 50 mg subcutaneously twice weekly for 3 months and then 50 mg once weekly for 9 months. Primary and safety end points were reported previously. Change from baseline to month 12 for the Dermatology Life Quality Index (DLQI), EuroQoL-5D, and Treatment Satisfaction Questionnaire for Medication (TSQM) are secondary outcomes reported here. Post hoc analyses of PROs are also reported.
RESULTS: Mean ± standard deviation (SD) DLQI total score improved from 13.7 ± 6.1 at baseline to 3.9 ± 5.6 at month 12. By month 12, 75% of patients achieved a clinically meaningful improvement in the DLQI (≥ 5-point improvement or a score of 0). Fifty-three to 86% of patients reported improvement or complete improvement in the six DLQI subscales. The mean ± SD EuroQoL-5D total score improved from baseline (0.67 ± 0.25) to month 12 (0.83 ± 0.25). The TSQM scores showed improvement in global satisfaction, effectiveness, and convenience after 3 months.
CONCLUSIONS: Etanercept was associated with improved PROs and increased treatment satisfaction over 1 year.
Authors:
Ron Vender; Charles Lynde; Martin Gilbert; Vincent Ho; Sheetal Sapra; Melanie Poulin-Costello
Related Documents :
15120376 - Laparoscopic distal pancreatectomy combined with preservation of the spleen for cystic ...
1359986 - Lack of feedback inhibition of insulin secretion in denervated human pancreas.
24526756 - No correlations between radiological angles and self-assessed quality of life in patien...
23970966 - Open reduction internal fixation poststernotomy mediastinitis.
25391306 - Early haemoperfusion with continuous venovenous haemofiltration improves survival of ac...
19568466 - Cyst ablation using a mixture of n-butyl cyanoacrylate and iodized oil in patients with...
Publication Detail:
Type:  Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cutaneous medicine and surgery     Volume:  16     ISSN:  1203-4754     ISO Abbreviation:  J Cutan Med Surg     Publication Date:    2012 Nov-Dec
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-04-16     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9614685     Medline TA:  J Cutan Med Surg     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  407-16     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Female
Humans
Immunoglobulin G / therapeutic use*
Male
Middle Aged
Patient Satisfaction*
Psoriasis / drug therapy*
Quality of Life*
Questionnaires
Receptors, Tumor Necrosis Factor / therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differentiation of rat dermal papilla cells into fibroblast-like cells induced by transforming growt...
Next Document:  Epidemiology of Sebaceous Carcinoma in Alberta, Canada, from 1988 to 2007.